Aptvirus

Aptivus is the clinical name for Tipranavir, a protease inhibitor used to slow the advance of serious viral diseases such as hepatitis and HIV. It was approved for use by the FDA on June 22, 2005 and is used in place of other inhibitors when the patient resists other drug combinations.

The creator of Aptivus, Boehringer Ingelheim, has received reports of brain bleeding and subsequent death by users of Aptivus. Of the 6,840 users of Aptivus, eight of those who suffered from brain bleeding died as a result. FDA investigations regarding Aptivus-related brain bleeding are ongoing.

If you or a loved one has suffered an injury, illness or death, that seems to have been someone else’s fault, call VanDerGinst Law at 1-866-843-7367 or click here for a FREE online case evaluation. The initial consultation is free of charge. If we agree to handle your injury case, we will work on a contingency fee basis, which means we get paid for our services only if, and when, there is a money recovery for you. In many cases a lawsuit must be filed before an applicable expiration date, known as a statute of limitations. So please call right away to ensure that you do not waive your right to possible compensation.

Links on the Web